Sign inJoin waitlistJoin the waitlist

Prakash Neupane

Program Director · University of Kansas School of Medicine

Credentials: · · · · ·

History

University of Kansas School of Medicine
Present
University of Kansas School of Medicine
Present
University of Kansas School of Medicine
Present

Hematology and Medical Oncology
LSU Health Sciences Center
1994–1997
Internal Medicine
St Barnabas Hospital
1991–1994
TRIBHUVAN UNIV, INST OF MED, MAHARAJGUNG, KATHMANDU, NEPAL
1987–1991

Research

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised,…
The Lancet · 2019 · 2,744 citations
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
Journal of Clinical Oncology · 2023 · 447 citations
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined…
Journal of Clinical Oncology · 2022 · 191 citations

Yelizaveta Shnayder
9 papers
Chao Huang
8 papers
Christopher Lominska
8 papers
Kiran Kakarala
6 papers
Barbara Burtness
5 papers
Gregory Gan
5 papers
JZ
Jun Zhang
5 papers
Antonio Jimeno
4 papers
BG
Burak Gumuscu
4 papers · 2 as a resident
Haoran Li
4 papers
Manidhar Lekkala
4 papers
Ryan Morse
4 papers · 2 as a resident

Clinical trials

S0217, Adjuvant Cisplatin and Docetaxel After Complete Resection Stage III or IV Head and Neck Cancer
Principal investigator · Withdrawn · Phase 2
SWOG Cancer Research Network
2005–2007
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2029
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Site PI · Recruiting
Tempus AI
2024–2028
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Site PI · Recruiting · Phase 2
NRG Oncology
2023–2032